Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiered trial of dinutuximab beta- and bevacizumab-based combinations for relapsed neuroblastoma
ISRCTN12532102Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Dinutuximab beta, bevacizumab, irinotecan and temozolomide in neuroblastoma (3 arms), sponsored by University of Birmingham. Primary endpoints: Progression-free survival and Safe and tolerable combination regimen. Started Nov 2024; status: recruiting.
02
Drugs
Dinutuximab betabevacizumabirinotecantemozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on ISRCTN12532102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12532102.